3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Erectile Dysfunction
8
Prostatic Neoplasms
7
Rectal Neoplasms
2
Neoplasms
2
Fatigue
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Solid Tumor
1
Sexuality
1
Sexual Dysfunction, Physiological
1
Sarcoma
1
Pre-Eclampsia
1
Postoperative Complications
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Mental Fatigue
1
Lymphoma, Follicular
1
Lymphatic Abnormalities
1
Lymphangioma
1
Infertility
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Erectile Dysfunction Following Radical Prostatectomy
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
82
Cisplatin
52
Oxaliplatin
36
lenvatinib
24
durvalumab
22
Capecitabine
22
Fluorouracil
20
Leucovorin
15
tislelizumab
11
pembrolizumab
10
apatinib
10
Radiotherapy
10
Albumin-Bound Paclitaxel
10
Radiofrequency Ablation
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Floxuridine
9
Liver Transplantation
8
Drug Therapy
8
Cholangiopancreatography, Endoscopic Retrograde
8
130-nm albumin-bound paclitaxel
8
Taxes
7
Platinum
7
Photochemotherapy
7
Panitumumab
7
Biopsy
7
1,2-diaminocyclohexaneplatinum II citrate
7
tremelimumab
6
pemigatinib
6
camrelizumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cholangiocarcinoma
×
Sildenafil Citrate
×
Clear all
NCT02106871
2017-10-27
PCC
The University of Texas Medical Branch, Galveston
Phase 1
Withdrawn